

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	X	N/A	N/A	N/A	N/A

*FHK- Florida Healthy Kids

Rexulti (brexpiprazole)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year
Medications	Quantity Limit
Rexulti (brexpiprazole)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Rexulti (brexpiprazole) may be approved when the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual is using for one of the following conditions:
 - A. Schizophrenia; **AND**
 1. The individual meets one of the following:
 - a. Individual is maintained on a stable dose of Rexulti; **OR**
 - b. Individual has had a trial of and inadequate response or intolerance to **one** preferred generic oral atypical antipsychotic; Preferred generic oral atypical antipsychotics: risperidone tablet/solution, olanzapine, quetiapine, ziprasidone, aripiprazole tablet, paliperidone; **OR**
 - c. The preferred generics are not FDA approved and do not have an accepted off-label use per the off-label policy for the prescribed indication and Rexulti does;
 - OR**
 - B. Major Depressive Disorder; **AND**
 1. Individual is maintained on a stable dose of Rexulti; **OR**
 2. Individual must use concomitant antidepressant therapy; **AND**
 3. Individual has had a trial of and inadequate response to aripiprazole.

NOTE: Rexulti (brexpiprazole) has a black box warning for an increased mortality risk in elderly individuals with dementia-related psychosis as well as increased risk of suicidal thoughts and behaviors in individuals 24 years in younger using antidepressant therapy. Elderly individuals with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. In trials, the cause of death varied, most appeared to be either cardiovascular or infectious in nature. Rexulti is not approved for use in individuals with dementia-related psychosis. Antidepressant therapy can increase suicidal thoughts and behaviors in individuals 24 years and younger. Monitoring is recommended for clinical worsening and emergence of suicidal thoughts and behaviors. Safety and effectiveness of Rexulti have not been established in pediatrics.

Key References:

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	NA	NA	NA	NA	NA	NA	NA	NA	NA	X	NA	N/A	N/A	NA

*FHK- Florida Healthy Kids

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2017. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed January 30, 2017.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2017; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.